OFI Invest Asset Management Has $31.87 Million Holdings in Boston Scientific Corporation $BSX

Key Points

• OFI Invest Asset Management increased its stake in Boston Scientific by 3,051.7% in the fourth quarter and now holds 334,242 shares worth $31.87 million according to its latest SEC filing.
• Analysts have trimmed price targets but remain mostly positive—MarketBeat reports an average rating of "Moderate Buy" with an average price target of $104.05, while shares trade around the low $60s.
• Key risks include a wave of class-action litigation notices and an investor probe into the proposed Penumbra acquisition, and CEO Michael Mahoney sold 160,901 shares, adding potential headline and execution risk.

OFI Invest Asset Management raised its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 3,051.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 334,242 shares of the medical equipment provider's stock after buying an additional 323,637 shares during the quarter. OFI Invest Asset Management's holdings in Boston Scientific were worth $31,870,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Parnassus Investments LLC raised its position in shares of Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider's stock worth $672,128,000 after purchasing an additional 6,868,459 shares during the period. Egerton Capital UK LLP raised its position in shares of Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider's stock worth $518,660,000 after purchasing an additional 3,671,548 shares during the period. Jennison Associates LLC raised its position in shares of Boston Scientific by 133.5% during the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider's stock worth $482,170,000 after purchasing an additional 2,823,744 shares during the period. Marshall Wace LLP raised its position in shares of Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider's stock worth $956,680,000 after purchasing an additional 2,301,383 shares during the period. Finally, Credit Agricole S A acquired a new position in shares of Boston Scientific during the third quarter worth approximately $204,812,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. The Goldman Sachs Group lowered their target price on Boston Scientific from $98.00 to $93.00 and set a "buy" rating on the stock in a research report on Friday, March 27th. Raymond James Financial reaffirmed an "outperform" rating and set a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Canaccord Genuity Group lowered their target price on Boston Scientific from $112.00 to $109.00 and set a "buy" rating on the stock in a research report on Tuesday, February 17th. Truist Financial lowered their target price on Boston Scientific from $95.00 to $92.00 and set a "buy" rating on the stock in a research report on Wednesday, March 18th. Finally, Mizuho decreased their price target on Boston Scientific from $140.00 to $115.00 and set an "outperform" rating for the company in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $104.05.

Boston Scientific Trading Up 1.3%

Shares of Boston Scientific stock opened at $62.69 on Thursday. The stock has a fifty day simple moving average of $72.73 and a 200 day simple moving average of $88.57. Boston Scientific Corporation has a 12-month low of $60.90 and a 12-month high of $109.50. The company has a market capitalization of $93.17 billion, a P/E ratio of 32.31, a price-to-earnings-growth ratio of 0.97 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the company posted $0.70 earnings per share. Boston Scientific's revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterated an "Outperform" after the CHAMPION‑AF readout met primary safety and efficacy endpoints, reinforcing the clinical story for BSX’s cardiac franchise and supporting buy‑side interest. Leerink Reiterates Outperform
• Positive Sentiment: Citigroup trimmed its price target (from $94 to $87) but kept a "Buy" rating, signaling continued analyst conviction that shares have upside despite recent share weakness. Citigroup Lowers PT
• Neutral Sentiment: Erste Group marginally cut FY2026 EPS (from $3.46 to $3.45) — a tiny revision that doesn’t materially change the consensus outlook but reflects modest near‑term estimate trimming. Erste Group Lowers Estimate
• Neutral Sentiment: An investor group is probing the proposed acquisition of Penumbra (the deal would pay cash or BSX shares). That scrutiny could slow or complicate deal completion and introduces execution risk if shareholder litigation or regulatory questions arise. Penumbra Sale Probe
• Negative Sentiment: Multiple law firms have filed or circulated investor alerts and class‑action notices accusing BSX and certain officers of securities violations for the period July 23, 2025–Feb 3, 2026; deadlines to seek lead‑plaintiff status are being publicized (notably May 4, 2026). The wave of litigation notices (Bragar Eagel & Squire, Robbins Geller, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Pomerantz, Rosen, Bernstein Liebhard, Gross, etc.) increases litigation risk, potential defense costs and headline volatility. Bragar Alert Robbins Geller Bronstein Faruqi

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.